Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895193 | 1.00 | CYP2C9 (0.41) | CYP2C9CYP3A4CYP2C19ERN1CYP2D6 | |
| SCHEMBL31026008 | 0.84 | ERN1 (0.38) | CYP2C9CYP3A4CYP2C19ERN1KDM4E | |
| SCHEMBL26113596 | 0.81 | ALDH1A1 (0.42) | KDM4E | |
| SCHEMBL30978619 | 0.78 | CTSL (0.36) | CYP2C9CYP3A4CYP2C19ERN1CYP2D6 | |
| SCHEMBL3973764 | 0.76 | ERN1 (0.47) | ERN1 | |
| SCHEMBL31396936 | 0.76 | ERN1 (0.47) | ERN1 | |
| SCHEMBL31685229 | 0.75 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19ERN1CYP2D6 | |
| SCHEMBL415893 | 0.75 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19ERN1CYP2D6 | |
| SCHEMBL29370127 | 0.75 | ERN1 (0.36) | ERN1KDM4E | |
| SCHEMBL1786787 | 0.75 | ERN1 (0.36) | ERN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115259168-B | Cell imprinting polymer with boric acid directional modification and PEG local post-modification, preparation method and application thereof | 天津医科大学 | 2024-07-09 | — | — | CN | claimed |
| CN-115254047-B | Molecularly imprinted and coated polymer, preparation method and application thereof | 南京大学 | 2024-01-02 | — | — | CN | claimed |
| CN-112098639-B | Synthesis and application of secondary antibody with graphene oxide as carrier | 天津医科大学 | 2024-01-02 | — | — | CN | claimed |
| CN-113512417-B | Synthesis and application of fluorescent signal amplifier with graphene oxide as carrier | 天津医科大学 | 2023-09-05 | — | — | CN | claimed |
| CN-111579467-B | Bifunctional graphene oxide composite material and application thereof in detecting adherent cells | 天津医科大学 | 2023-03-14 | — | — | CN | claimed |
| CN-115254047-A | Molecular imprinting and coating polymer, preparation method and application thereof | 南京大学 | 2022-11-01 | — | — | CN | claimed |
| CN-115259168-A | Cell imprinting polymer with boric acid directional modification and PEG local post-modification, preparation method and application thereof | 天津医科大学 | 2022-11-01 | — | — | CN | claimed |
| CN-113512417-A | Synthesis and application of fluorescent signal amplifier with graphene oxide as carrier | 天津医科大学 | 2021-10-19 | — | — | CN | claimed |
| CN-108722369-B | Universal convenient epitope imprinting method and application of obtained molecularly imprinted polymer | 南京大学 | 2020-12-25 | — | — | CN | claimed |
| CN-112098639-A | Synthesis and application of secondary antibody taking graphene oxide as carrier | 天津医科大学 | 2020-12-18 | — | — | CN | claimed |
| CN-111579467-A | Bifunctional graphene oxide composite material and application thereof in detecting adherent cells | 天津医科大学 | 2020-08-25 | — | — | CN | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250128188-A1 | BORONIC ACID CONTAINING AFFINITY MEMBRANES | DONALDSON COMPANY, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CYP2C9 2712/4885CYP3A4 2838/4885CYP2C19 2573/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | CYP2C9 4207/4885CYP3A4 4165/4885CYP2C19 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.